In this large randomized , placebo-controlled trial among heterosexual persons , with median follow-up of 18 months and maximum follow-up of 36 months , daily oral TDF-based PrEP resulted in a small but nonprogressive decline in eGFR that was not accompanied by a substantial increase in the risk of clinically relevant ( 25 % ) eGFR decline .